CompletedNCT00572793

A Study to Evaluate the Use of Placenta Protein 13 (PP13) in the First Trimester of Pregnancy as a Diagnostic Aiding Tool in the Assessment of the Risk for Developing Preeclampsia in Women With Low and Unknown Risk

Studying Preeclampsia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Carl Weiner, MD
Principal Investigator
Carl Weiner, MD, MBA
University of Kansas Medical Center
Enrollment
431 target
Eligibility
16-45 years · FEMALE
Timeline
2007 – 2014

Study locations (1)

Collaborators

Diagnostic Technologies Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00572793 on ClinicalTrials.gov

Other trials for Preeclampsia

Additional recruiting or active studies for the same condition.

See all trials for Preeclampsia →

← Back to all trials